Tag: Integrin antagonist

Clinical trials for multiple sclerosis (MS) showed that TYSABRI reduced the number of relapses by 67% compared to placebo over two years. The question is, what are the benefits of TYSABRI and how does this powerful monoclonal antibody help patients with MS and Crohn's disease?

In a two-year clinical trial, Tysabri was shown to significantly decrease the number of relapses experienced by patients with relapsing-remitting MS. So, **does Tysabri reduce inflammation**? Yes, it is a highly effective treatment that specifically prevents the migration of inflammatory immune cells into the central nervous system and intestinal mucosa.

Natalizumab, an immunosuppressant, was temporarily withdrawn from the market in 2005 due to safety concerns regarding a rare brain infection, before being re-approved with a restricted program in 2006. Its classification is complex, primarily as a selective adhesion molecule inhibitor and a monoclonal antibody.

Over 2.8 million people worldwide live with multiple sclerosis, and natalizumab (Tysabri) is a powerful, targeted treatment option for relapsing forms of the disease. What type of drug is natalizumab? It is a specialized monoclonal antibody that acts as a selective immunosuppressant.